According to the Futurism website Beijing time on March 8, just as doctors use the improved T cells of the patient's immune system to treat cancer, biotechnology startup Rubius Therapeutics hopes to use red blood cells to treat some rare diseases.
According to media reports, Torben Straight Nissen, CEO of Rubius Therapeutics, believes that their therapy is basically 'super blood' because the company's treatment is the use of red blood cells rather than chemicals. Or synthetic material.
Rubius Therapeutics plans to add medical proteins to red blood cells and adjust them accordingly. After that, these red blood cells will be injected into patients to start treating their diseases. Ultimately, this 'super blood' only accounts for the total blood in the patient's body. The amount of 1% or less.
Originally, Rubius Therapeutics wanted to develop super blood therapy that replaces missing enzymes in patients with rare diseases, as well as treat cancers and autoimmune diseases such as lupus and type 1 diabetes. However, unlike T cell therapy, red blood cell therapy is universally applicable. Sex.
According to the Rubius Therapeutics website, they need only one universal donor (a donor with negative O blood) that will produce enough therapeutic doses to treat hundreds or even thousands of patients. "The company Seems to be doing this in an orderly fashion, with just a new round of financing of $ 100 million recently completed and in June 2017 it has received $ 120 million in funding.
Nissens pointed out in a statement that the 'new round of financing further strengthened our position and enabled us to accelerate the development of the first RCTs to treat enzyme deficiency, cancer and autoimmune diseases.' We have a talented team of investors, leaders and consultants who have the same long-term vision of delivering novel cell-based therapies to patients. "
Rubus Therapeutics may take a long time to get widespread use, after all, these therapies are currently only a concept, first of all, these therapies must really be developed and then through a series of clinical trials to determine the effectiveness of If all goes well, 'Super Blood' should eventually get the FDA's approval, just like 2017's T cell therapy.